Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

C1-inactivator is upregulated in glioblastoma

Förnvik, Karolina LU orcid ; Maddahi, Aida LU ; Persson, Oscar LU ; Osther, Kurt ; Salford, Leif G. LU and Nittby Redebrandt, Henrietta LU (2017) In PLoS ONE 12(9).
Abstract

Background: Glioblastoma is the most common and aggressive type of primary brain tumor in adults. A key problem is the capacity of glioma cells to inactivate the body’s immune response. The complement system acts as a functional bridge between the innate and adaptive immune response. Still, the role of the complement system has almost been forgotten in glioma research. In our present study, we hypothesize that C1 inactivator (C1-IA) is upregulated in astrocytoma grade IV, and that its inhibition of the complement system has beneficial effects upon survival. Methods and results: We have explored this hypothesis both on gene and protein levels and found an... (More)

Background: Glioblastoma is the most common and aggressive type of primary brain tumor in adults. A key problem is the capacity of glioma cells to inactivate the body’s immune response. The complement system acts as a functional bridge between the innate and adaptive immune response. Still, the role of the complement system has almost been forgotten in glioma research. In our present study, we hypothesize that C1 inactivator (C1-IA) is upregulated in astrocytoma grade IV, and that its inhibition of the complement system has beneficial effects upon survival. Methods and results: We have explored this hypothesis both on gene and protein levels and found an upregulation of C1-IA in human glioblastoma cells using data from a publicly available database and our own mRNA material from glioblastoma patients. Furthermore, we demonstrated the presence of C1-IA by using immunohistochemistry on glioma cells from both humans and rats in vitro. Finally, we could demonstrate a significantly increased survival in vivo in animals inoculated intracerebrally with glioma cells pre-coated with C1-IA antibodies as compared to control animals. Conclusions: Our findings indicate that overexpression of C1-IA is present in glioblastomas. This could be demonstrated both at the gene level from patients with glioblastoma, on mRNA level and with immunohistochemistry. Treatment with antibodies against C1-IA had beneficial effects on survival when tested in vivo.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
glioblastoma, C1-inactivator
in
PLoS ONE
volume
12
issue
9
article number
e0183086
publisher
Public Library of Science (PLoS)
external identifiers
  • scopus:85029001424
  • pmid:28880870
  • pmid:28880870
  • wos:000409467200013
ISSN
1932-6203
DOI
10.1371/journal.pone.0183086
language
English
LU publication?
yes
id
00acea34-72b2-4de9-88cc-d89470533970
date added to LUP
2017-10-09 16:59:19
date last changed
2024-06-24 01:47:19
@article{00acea34-72b2-4de9-88cc-d89470533970,
  abstract     = {{<p>Background: Glioblastoma is the most common and aggressive type of primary brain      tumor      in adults. A key problem is the capacity of glioma cells to inactivate      the body’s      immune response. The complement system acts as a functional bridge      between the innate      and adaptive immune response. Still, the role of the complement      system has almost      been forgotten in glioma research. In our present study, we      hypothesize that C1 inactivator      (C1-IA) is upregulated in astrocytoma grade      IV, and that its inhibition of the complement      system has beneficial effects      upon survival. Methods and results: We have explored      this hypothesis both on      gene and protein levels and found an upregulation of C1-IA      in human glioblastoma      cells using data from a publicly available database and our      own mRNA material      from glioblastoma patients. Furthermore, we demonstrated the presence      of C1-IA      by using immunohistochemistry on glioma cells from both humans and rats      in vitro.      Finally, we could demonstrate a significantly increased survival in vivo      in      animals inoculated intracerebrally with glioma cells pre-coated with C1-IA antibodies      as      compared to control animals. Conclusions: Our findings indicate that overexpression      of      C1-IA is present in glioblastomas. This could be demonstrated both at the gene      level      from patients with glioblastoma, on mRNA level and with immunohistochemistry.      Treatment      with antibodies against C1-IA had beneficial effects on survival when tested      in      vivo.</p>}},
  author       = {{Förnvik, Karolina and Maddahi, Aida and Persson, Oscar and Osther, Kurt and Salford, Leif G. and Nittby Redebrandt, Henrietta}},
  issn         = {{1932-6203}},
  keywords     = {{glioblastoma; C1-inactivator}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{9}},
  publisher    = {{Public Library of Science (PLoS)}},
  series       = {{PLoS ONE}},
  title        = {{C1-inactivator is upregulated in glioblastoma}},
  url          = {{http://dx.doi.org/10.1371/journal.pone.0183086}},
  doi          = {{10.1371/journal.pone.0183086}},
  volume       = {{12}},
  year         = {{2017}},
}